摘要
Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulinM (IgM) monoclonal anti-myelin-associat ed glycoprotein(MAG) neuropathies. We report a patient with an autonomicand pain ful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, resp onsive to rituximab. Treatment resulted in a decline in total IgM and improvemen t in the patient’s painful neuropathy and dysautonomia. Rituximab maybe an effe ctive and tolerable treatment for autonomic and sensory neuropathy associated wi th IgM monoclonal gammopathy.
Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulinM (IgM) monoclonal anti-myelin-associat ed glycoprotein(MAG) neuropathies. We report a patient with an autonomicand pain ful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, resp onsive to rituximab. Treatment resulted in a decline in total IgM and improvemen t in the patient's painful neuropathy and dysautonomia. Rituximab maybe an effe ctive and tolerable treatment for autonomic and sensory neuropathy associated wi th IgM monoclonal gammopathy.
出处
《世界核心医学期刊文摘（神经病学分册）》
2005年第8期51-51,共1页
Digest of the World Core Medical Journals:Clinical Neurology
